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ABSTRACT: Based on a combination of an Ugi four component reaction and a
ring closing metathesis, a library of novel artiﬁcial macrocyclic inhibitors of the
p53−MDM2 interaction was designed and synthesized. These macrocycles,
alternatively to stapled peptides, target for the ﬁrst time the large hydrophobic
surface area formed by Tyr67, Gln72, His73, Val93, and Lys94 yielding
derivatives with aﬃnity to MDM2 in the nanomolar range. Their binding aﬃnity
with MDM2 was evaluated using ﬂuorescence polarization (FP) assay and
1H−15N two-dimensional HSQC nuclear magnetic resonance experiments.
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In nature, macrocycles are not uncommon and often exhibitinteresting biological activities.1 Often macrocyclic com-
pounds have distinct advantages over their open chain analogues
including higher aﬃnity and selectivity,2 preferable entropic
signature, better membrane permeation, and oral bioavailability
or higher stability.1,2 Thus, macrocycles can increase aﬃnity and
selectivity for a speciﬁc target.1 In spite of their potential,
macrocycles pose considerable synthesis problems, and also, the
accurate prediction of their conformation makes it diﬃcult to
predict activity.1,2
The tumor suppressor protein p53 is involved in controlling
pathways of cell cycle, apoptosis, angiogenesis metabolism,
senescence, and autophagia.3,4 The TP53 gene is one of the most
frequently mutated genes in a multitude of human cancer.5
Additionally, in multiple cases where TP53 is intact, p53’s
function is impaired by its negative regulators, mouse double
minute 2 and 4 homologues (MDM2 and MDMX), due to
ampliﬁcation or enhanced expression of their coding genes.3−5
Multiple potent and selective compound classes to inhibit the
p53−MDM2 interaction have been discovered, described, and
evaluated in early clinical trials.6 However, the pharmacokinetic
and pharmacodynamics properties of the studied scaﬀolds could
still be optimized to minimize the side eﬀects. Thus, the
discovery of new p53−MDM2 inhibitors with diverse structures
to improve their properties is still of importance.6−8 The three
ﬁnger pharmacophore model for p53−MDM2 is recognized as
responsible for the binding of small molecules and peptides to
the MDM2.9,10 We already described several series of potent
p53−MDM2 antagonists, proposing an extended four ﬁnger
model; the intrinsically disordered MDM2 N-terminus is
ordered by certain small molecules, which can be obtained by
multicomponent reaction chemistry,11,12 as shown by cocrystal-
lization.13,14 Recently, several macrocyclic stapled peptides have
been described with great aﬃnity toward MDM2 and MDMX.6
ALRN-6924 (Aileron Therapeutics) is currently undergoing
phase I and II clinical trials in patients suﬀering from solid
tumors, lymphoma, and myeloid leukemias (ClinicalTrials.gov
ID: NCT02264613 and NCT02909972).
Here, we propose a novel series of nonpeptidic artiﬁcial
macrocyclic compounds that inhibit the p53−MDM2 inter-
action, which might have a diﬀerent activity proﬁle from the
currently available scaﬀolds. Our synthesis strategy is shown in
Figure 1. Based on the Ugi scaﬀold, we introduced two terminal
Received: May 23, 2017
Accepted: September 20, 2017
Published: September 20, 2017
Figure 1. Macrocyclization strategy to inhibit the p53−MDM2
interaction.
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ene-functionalities via the carboxylic acid and the isocyanide
component, and we were able to cyclize the compounds by ring
closing metathesis (RCM, Figure 1).15,16
Our previously introduced three and four-point pharmaco-
phore models were the basis of the discovery and development of
the current inhibitors. Thus, we used as the starting point our
formerly described α-aminoacylamide (YH300, shown in cyan
sticks, Figure 2) with a Ki of 600 nM and its crystal structure in
complex withMDM2 receptor (PDB ID 4MDN).13 Accordingly,
the 6-chloroindole-2-carboxylic acid was used as an “anchor” in
order to mimic the Trp23 amino acid and constrain the position
of other substituents, and three additional binding sites were
deﬁned, Phe19, Leu26, and the induced Leu26 subpocket.
Our design of the macrocyclic linker aims to bind on top of the
loop linking α2′ and α1′ helices, covering a large hydrophobic
surface area formed by Tyr67, Gln72, His73, Val93, and Lys94
(Figure 2) and potentially increasing the aﬃnity to the receptor.
Moreover, we reasoned that the addition of a methyl group on
the ring could mimic the tert-butyl group of YH300,13 likely
leading to increased aﬃnity.
The retrosynthetic plan of the designed macrocycle 1 foresees
(Scheme 1) a ring closing metathesis reaction (RCM), followed
by a classical Ugi four-component (U-4CR). The Ugi adduct is
formed of the anchoring 6-chloro-3-carboxaldehyde 6, suitably
substituted benzylamines 5, and the long-chained aliphatic
carboxylic acids 8 along with the isocyanides 7 incorporating
terminal double bonds.
Aldehyde 6 was synthesized from the 6-chloro-indole
derivative using the Vilsmeier−Haack formylation reaction.17,18
For the preliminary structure−activity relationship (SAR)
analysis of the Leu26 and the induced pockets, the benzylamines
5 were used as commercially available (5b−h) or obtained via
Williamson ether synthesis (5a). Probing both the Phe19 pocket
and the larger hydrophobic surface area formed by Tyr67, Gln72,
His73, Val93, and Lys94, the isocyanides 7a,b were synthesized
from the corresponding formamides, whereas the carboxylic
acids are commercially available. In particular, the amine 5a with
the oxygen linker that was designed to probe the induced pocket
was synthesized through a Williamson ether synthesis of the
protected 4-hydroxybenzylamine with the 3,4-benzyl chloride
under basic conditions (Supporting Information (SI), Scheme
1). The isocyanides 7a,b were synthesized from the formamides
via the revised Leuckart−Wallach reaction of the corresponding
carbonyl compounds (SI, Scheme 2).19
Next, we proceeded in the Ugi four-component reaction.
Equimolar mixture of the substituted benzylamine 5, aldehyde 6,
isocyanide 7, and carboxylic acid 8 in 2,2,2-triﬂuoroethanol
(TFE) was irradiated at 120 °C for 1 h in a microwave oven
yielding compounds 4 (Scheme 2). Afterward, we successfully
performed the ring closing metathesis with the second
generation of Grubbs catalyst in dichloromethane (DCM)
aﬀording compounds 3 as mixture of isomers (E and Z). Due to
the fact that the existence of the double bond gives rise to two
possible isomers and most importantly reduces the ﬂexibility of
the macrocycle, we decided to subject the mixture to hydro-
genation on Pd/C isolating compounds 2. The last step was the
ester hydrolysis obtaining the ﬁnal screening compounds 1
(Scheme 2). Performing a preliminary SAR, we built a small
Figure 2. Four- and three-point pharmacophore modeling of macrocyclic compounds. Left: YH300 (PDB ID: 4MDN, cyan lines), Tyr67, Gln72, His73,
Val93, and Lys94 (blue sticks), proposed macrocycle to explore the four-pharmacophore point (pink sticks). Right: SAH-p53−8 stapled-peptide (PDB
ID: 3V3B, cyan lines), Tyr67, Gln72, His73, Val93, and Lys94 (blue sticks), proposed macrocycle to explore the three-pharmacophore point (pink
sticks).
Scheme 1. Retrosynthetic Plan Based on a U-4CR and a Ring Closing Metathesis
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library of macrocycles of various ring sizes (12, 13, 18, 19, and 24
number of atoms) targeting the hydrophobic region around
Tyr67, Gln72, His73, Val93, and Lys94. We maintained the
anchoring indole group for the Trp23 and the phenyl group for
Leu26 and further explored the induced pocket with the
extended dichlorobenzyloxy moiety.
Two complementary assays based on independent phys-
icochemical principles, ﬂuorescence polarization (FP) and
1H−15N 2D HSQC nuclear magnetic resonance (NMR) were
used to measure aﬃnity and to exclude false positive hits. FP
assay was employed to determine the inhibitory aﬃnities (Ki) of
the macrocycles against MDM2 as previously described,20 and
the results are presented in Table 1.
Examining both the three- and four-ﬁnger pharmacophore
model, it seems that most of the obtained macrocycles are active
toward MDM2, many of them demonstrating an aﬃnity below 1
μM. Although it is a preliminary SAR study, we can conclude that
the ideal ring size for the four-ﬁnger model seems to be around
18 (entry 3). The aﬃnity improves while increasing the size from
12 (1a, entry 1) to 13 (1b, entry 2) and eventually 18 (1c, entry
3) atom ring size. Moreover, compound 1c has an aﬃnity of 100
nM as a mixture of diastereomers, whereas the larger 24-
membered macrocycle 1k (entry 11) shows decreased activity
(1.91 μM).
In addition, we focused on the three-ﬁnger-pharmacophore
model, which characterizes the vast majority of the currently
Scheme 2. Synthesis of the Macrocycle Library Based on the U-4CR/RCM Strategy
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available small-molecule MDM2 inhibitors.6 We synthesized
various macrocycles with a diﬀerent substitution pattern. The
position of halogens on the phenyl group seems to play a
signiﬁcant role since the para ﬂuoro (1d, entry 4) or chloro
substituted (1f, entry 6) derivatives are only slightly or not active
at all. On the contrary, the addition of a second chlorine in o- or
m-position inﬂuenced the binding mode, the 2,4-dichloro
derivative (1e) showed activity of 5.3 μM (entry 5,) and the
corresponding 3,4-dichloro compound 1h (entry 8) displayed an
activity of 80 nM. Whereas placing the donor group −OMe in
compound 1g (entry 7) improved the aﬃnity with 1.3 μM.
Nonetheless, m-OMe substitution, keeping the same ring size of
18 (1i, entry 9), did not show any signiﬁcant diﬀerence,
exhibiting an activity of 1.8 μM. Due to our previous results,21
where we were able to synthesize ﬂuorinated phenyls such as
compound 9 with Ki up to 100 nM, we employed the 3,4,5-
triﬂuorobenzylamine and we synthesized compound 1j (entry
10), which exhibited an interesting aﬃnity as a racemic mixture
of 140 nM. Enantiomeric separation of the racemic mixture via
chiral SFC provided the enantiomers (+)-1ja and (−)-1jb with
aﬃnities of 90 and 700 nM, respectively. As it was expected, the
separated enantiomers showed a signiﬁcant increase of the
activity compared to the racemic mixture.
The existence of the double bond in the macrocycles 3j and 3k,
as anticipated, reduced signiﬁcantly the aﬃnity to 340 nM and
2.5 μM, respectively (entries 12 and 13), compared with the
corresponding hydrogenated compounds 1j (Ki = 140 nM) and
1k (Ki = 1.9 μM). The corresponding esters, 2a and 2k (entries
14 and 15), are orders of magnitude less reactive or inactive
comparing with the acids in accordance with our previous
experience (entries 1 and 11).11,12,22−25 Interestingly, the acyclic
Ugi-adduct 4j was also proven to be practically inactive both in
the ester and acid forms (SI, Table S1, entry 15). Moreover,
changing the anchor to a nonsubstituted indole moiety
(compound 10) or to the 3- or 4-phenyl moiety (compound
11), resulted in nearly no activity.
The expected ligand-induced perturbations in 1H−15N 2D
HSQCNMR spectra were indeed observed (Figure 3). The 15N-
labeled MDM2 was titrated with increasing concentration of the
compound. Since all cross peaks in the MDM2 spectrum were
assigned to particular amino acid residues,26 it was possible to
analyze the interaction within the MDM2/1j complex.
Particularly, Val93 is clearly involved in the interaction, as its
cross peak shifted between titration steps for MDM2/1j molar
ratios equal to 2:1 and 1:1. After 1:1 step, the peak remained in
the same position. NMR titration also conﬁrmed the tight
binding of 1j, as, e.g., for Arg29, NMR signal splitting was
observed (Figure 3), which indicated strong interaction with
MDM2 at Kd below 1 μM (and a slow chemical exchange).
Three of themacrocyclic compounds (1c, 1h, and 1j) obtained
demonstrated improved binding aﬃnities (Ki ≈ 100 nM) over
the lead acyclic molecule, YH300 (Ki = 600 nM). In order to
rationalize the tight receptor ligand interaction, we exploit
modeling studies using MOLOC27 based on the HSQC binding
data having as template a known cocrystal structure (PDB ID:
3TU1)21 and the small network analysis using Scorpion software
(Figure 4).28 It revealed the existence of van der Waals
interactions of the aliphatic handle with Tyr67 and His73, the
expected alignment of the 6-chloro-indole moiety of the
designed compounds with the p53Trp23 pocket, whereas the
Table 1. Results of the Evaluation of Inhibitory Activity of
Macrocyclic Inhibitors toward MDM2 Using FP Assaya
entry compound ring size Ki (μM)
1 1a 12 0.35
2 1b 13 0.32
3 1c 18 0.10
4 1d 18 N/A
5 1e 18 5.3
6 1f 18 N/A
7 1g 18 1.3
8 1h 18 0.08
9 1i 18 1.8
10 1j 19 0.14 (rac-1j)
0.09 {(+)-1ja}
0.70 {(−)-1jb}
11 1k 24 1.9
12 3j 19 0.34
13 3k 24 2.5
14 2a 12 3.0
15 2k 24 N/A
aN/A: not active; all measurements performed in duplicates; standard
errors up to 10%.
Figure 3. Spectrum of the 15N-labeled MDM2 (blue) superimposed
with spectrum after addition of 1j in a MDM2/1j molar ratio equal to
2:1 (red) and 1:1 (green). The close-up view shows selected peaks
assigned to Val93 and Arg29. For Arg29, NMR signal splitting indicates
strong interaction at Kd below 1 μM.
Figure 4. Small network analysis of 1j (white sticks) modeled into the
MDM2 receptor (PDB ID: 3TU1, cyan sticks): π−π and van der Waals
interactions are shown in orange and yellow dotted lines, respectively.
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3,4,5-triﬂuorophenyl ring occupied the p53Leu26 hydrophobic
pocket. Moreover, the π−π interaction of His96 with the 3,4,5-
triﬂuorophenyl fragment and several van der Waals interactions
with Leu54, Ile61, Phe86, Phe91, Val93, His96, and Tyr100 are
depicted. These ﬁndings support our initial hypothesis of the
divergent hydrophobic handle position compared to staple
peptides shown before,29−34 suggesting a new approach to
improve and diversify the extensive collection of MDM2/X
inhibitors.
To analyze and compare the physicochemical properties of our
newly synthesized macrocycles with the orally available macro-
cycle drugs,35 we plotted molecular weight, clogP, topological
polar surface area (TPSA), number of hydrogen bond donors
(HBDs), hydrogen bond acceptors (HBAs), and number of
rotatable bonds (RB) (Figure 5). Interestingly, the values of the
properties in most of our macrocycles are set in the appropriate
range, demonstrating the signiﬁcance of this new strategy to
develop potentially oral bioavailable macrocycles targeting the
p53−MDM2 interaction. In the case of 1c and 1k, clogP goes oﬀ
the limits as expected since we were targeting a very lipophilic
surface. However, this will be overcome in the future with a
strategy to incorporate heteroatoms (oxygens) on both the acid
and isocyanide linker. After this initial SAR study, we will in the
future synthesize libraries of novel macrocycles as potent p53−
MDM2 inhibitors with higher diversity and complexity.
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(18) Dömling, A.; Holak, T. Novel p53-mdm2/p53-mdm4 Antago-
nists to Treat Proliferative Disease. Patent application WO2011106650
A3, 2012.
(19) Neochoritis, C. G.; Zarganes-Tzitzikas, T.; Stotani, S.; Dömling,
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Bis(1′H-Indole) Heterocycles: New p53/MDM2/MDMX Antagonists.
Bioorg. Med. Chem. Lett. 2015, 25 (24), 5661−5666.
(23) Czarna, A.; Beck, B.; Srivastava, S.; Popowicz, G. M.; Wolf, S.;
Huang, Y.; Bista, M.; Holak, T. A.; Dömling, A. Robust Generation of
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